Related Experiment Video
Updated: May 2, 2026

Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
Published on: February 25, 2022
Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased
James A Austin1, Gareth S A Wright, Seiji Watanabe
1Molecular Biophysics Group, Institute of Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool L69 7ZB, United Kingdom.
Abstract:
Over the last two decades many secrets of the age-related human neural proteinopathies have been revealed. A common feature of these diseases is abnormal, and possibly pathogenic, aggregation of specific proteins in the effected tissue often resulting from inherent or decreased structural stability. An archetype example of this is superoxide dismutase-1, the first genetic factor to be linked with amyotrophic lateral sclerosis (ALS). Mutant or posttranslationally modified TAR DNA binding protein-32 (TDP-43) is also strongly associated with ALS and an increasingly large number of other neurodegenerative diseases, including frontotemporal lobar degeneration (FTLD). Cytoplasmic mislocalization and elevated half-life is a characteristic of mutant TDP-43. Furthermore, patient age at the onset of disease symptoms shows a good inverse correlation with mutant TDP-43 half-life. Here we show that ALS and FTLD-associated TDP-43 mutations in the central nucleic acid binding domains lead to elevated half-life and this is commensurate with increased thermal stability and inhibition of aggregation. It is achieved without impact on secondary, tertiary, or quaternary structure. We propose that tighter structural cohesion contributes to reduced protein turnover, increasingly abnormal proteostasis and, ultimately, faster onset of disease symptoms. These results contrast our perception of neurodegenerative diseases as misfolded proteinopathies and delineate a novel path from the molecular characteristics of mutant TDP-43 to aberrant cellular effects and patient phenotype.
Insights
Mutant TAR DNA binding protein-32 (TDP-43) mutations increase protein stability, slowing turnover and accelerating neurodegenerative disease onset in ALS and FTLD. This challenges the view of protein misfolding as the sole driver.
Area of Science:
- Neuroscience
- Molecular Biology
- Protein Biochemistry
Background:
- Age-related neural proteinopathies, like ALS and FTLD, involve abnormal protein aggregation.
- Mutant TAR DNA binding protein-32 (TDP-43) is linked to ALS and FTLD, characterized by mislocalization and longer half-life.
- Patient age at disease onset inversely correlates with mutant TDP-43 half-life.
Purpose of the Study:
- To investigate how ALS and FTLD-associated TDP-43 mutations affect protein stability, half-life, and aggregation.
- To explore the relationship between structural changes in mutant TDP-43 and disease onset.
Main Methods:
- Analysis of TDP-43 mutations in nucleic acid binding domains.
- Assessment of protein half-life, thermal stability, and aggregation propensity.
- Evaluation of structural integrity (secondary, tertiary, quaternary).
Main Results:
- TDP-43 mutations in central nucleic acid binding domains increase protein half-life.
- Increased half-life correlates with enhanced thermal stability and inhibited aggregation.
- Structural integrity (secondary, tertiary, quaternary) remains unaffected.
Conclusions:
- Tighter structural cohesion in mutant TDP-43 leads to reduced protein turnover and abnormal proteostasis.
- This molecular mechanism contributes to a faster onset of neurodegenerative disease symptoms.
- Findings suggest a novel pathway from mutant TDP-43 molecular characteristics to cellular effects and patient phenotype, contrasting traditional protein misfolding paradigms.
Related Concept Videos
Abnormal Proliferation
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Microtubule Instability
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Translation
Translation Produces the Building Blocks of Life
Proteins are...
RNA Stability

